Marina Gaínza-Lein1, Iván Sánchez Fernández2, Adriana Ulate-Campos3, Tobias Loddenkemper4, Adam P Ostendorf5. 1. Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; Facultad de Medicina, Universidad Austral de Chile, Valdivia, Chile. Electronic address: m.gainzalein@gmail.com. 2. Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; Department of Child Neurology, Hospital Sant Joan de Déu, Universidad de Barcelona, Spain. Electronic address: ivan.fernandez@childrens.harvard.edu. 3. Department of Neurology, National Children's Hospital "Dr. Carlos Saenz Herrera", San José, Costa Rica. Electronic address: adrianaulate@hotmail.com. 4. Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: tobias.loddenkemper@childrens.harvard.edu. 5. Neurology Division, Department of Pediatrics, The Ohio State University and Nationwide Children's Hospital, Columbus, OH, USA. Electronic address: Adam.Ostendorf@nationwidechildrens.org.
Abstract
OBJECTIVE: Describe basic science, animal models and clinical data related to timing of treatment in status epilepticus (SE). METHODS: We summarized the results of 15 studies that reported time to treatment in SE, and reviewed basic and clinical literature. RESULTS: SE is a life-threatening and time-sensitive emergency that requires immediate treatment. Current guidelines recommend escalation of anti-seizure medications (ASM) within specified time frames. Prolonged seizures may lead to changes in the composition and location of gamma-aminobutyric acid A receptors (GABAAR) and N-Methyl-d-aspartic acid receptors (NMDAR), leading to loss of inhibition and increased excitation. These biochemical changes are apparent in specific animal models having progressive resistance to benzodiazepines (BZD) with longer seizures. Later treatments lead to decreased response to BZD, longer seizures, greater need of continuous infusions, potential brain injury and increased in-hospital mortality. Despite mounting evidence that early treatment of SE is more effective and safer, treatment and ASM escalation is often delayed compared to protocols. Literature review of 2212 patients with SE showed an average time to treatment of 42.4 min and time to hospital arrival of 56 min. Also, only 51.8% of patients received treatment by emergency medical services and 12.8% by their families, including patients with a previous diagnosis of epilepsy or with prior SE. CONCLUSIONS: Morbidity and mortality may be avoided with rapid, effective treatment of SE. Treatment application and escalation remains delayed especially in outpatient settings, potentially leading to suboptimal outcomes. Implementation techniques and quality improvement methodologies may provide avenues for improving outcomes in SE.
OBJECTIVE: Describe basic science, animal models and clinical data related to timing of treatment in status epilepticus (SE). METHODS: We summarized the results of 15 studies that reported time to treatment in SE, and reviewed basic and clinical literature. RESULTS: SE is a life-threatening and time-sensitive emergency that requires immediate treatment. Current guidelines recommend escalation of anti-seizure medications (ASM) within specified time frames. Prolonged seizures may lead to changes in the composition and location of gamma-aminobutyric acid A receptors (GABAAR) and N-Methyl-d-aspartic acid receptors (NMDAR), leading to loss of inhibition and increased excitation. These biochemical changes are apparent in specific animal models having progressive resistance to benzodiazepines (BZD) with longer seizures. Later treatments lead to decreased response to BZD, longer seizures, greater need of continuous infusions, potential brain injury and increased in-hospital mortality. Despite mounting evidence that early treatment of SE is more effective and safer, treatment and ASM escalation is often delayed compared to protocols. Literature review of 2212 patients with SE showed an average time to treatment of 42.4 min and time to hospital arrival of 56 min. Also, only 51.8% of patients received treatment by emergency medical services and 12.8% by their families, including patients with a previous diagnosis of epilepsy or with prior SE. CONCLUSIONS: Morbidity and mortality may be avoided with rapid, effective treatment of SE. Treatment application and escalation remains delayed especially in outpatient settings, potentially leading to suboptimal outcomes. Implementation techniques and quality improvement methodologies may provide avenues for improving outcomes in SE.
Authors: Richard J Burman; Joshua S Selfe; John Hamin Lee; Maurits van den Berg; Alexandru Calin; Neela K Codadu; Rebecca Wright; Sarah E Newey; R Ryley Parrish; Arieh A Katz; Jo M Wilmshurst; Colin J Akerman; Andrew J Trevelyan; Joseph V Raimondo Journal: Brain Date: 2019-11-01 Impact factor: 13.501
Authors: Theodore Sheehan; Marta Amengual-Gual; Alejandra Vasquez; Nicholas S Abend; Anne Anderson; Brian Appavu; Ravindra Arya; Cristina Barcia Aguilar; J Nicholas Brenton; Jessica L Carpenter; Kevin E Chapman; Justice Clark; Raquel Farias-Moeller; William D Gaillard; Marina Gaínza-Lein; Tracy A Glauser; Joshua L Goldstein; Howard P Goodkin; Réjean M Guerriero; Linda Huh; Michele Jackson; Kush Kapur; Robert Kahoud; Yi-Chen Lai; Tiffani L McDonough; Mohamad A Mikati; Lindsey A Morgan; Edward J Novotny; Adam P Ostendorf; Eric T Payne; Katrina Peariso; Juan Piantino; Latania Reece; James J Riviello; Tristan T Sands; Kumar Sannagowdara; Renee Shellhaas; Garnett Smith; Robert C Tasker; Dmitry Tchapyjnikov; Alexis A Topjian; Mark S Wainwright; Angus Wilfong; Korwyn Williams; Bo Zhang; Tobias Loddenkemper Journal: Epilepsia Date: 2021-08-21 Impact factor: 6.740
Authors: Abhishek G Sathe; Holly Tillman; Lisa D Coles; Jordan J Elm; Robert Silbergleit; James Chamberlain; Jaideep Kapur; Hannah R Cock; Nathan B Fountain; Shlomo Shinnar; Daniel H Lowenstein; Robin A Conwit; Thomas P Bleck; James C Cloyd Journal: Acad Emerg Med Date: 2019-07-18 Impact factor: 5.221
Authors: Iván Sánchez Fernández; Nicholas S Abend; Marta Amengual-Gual; Anne Anderson; Ravindra Arya; Cristina Barcia Aguilar; James Nicholas Brenton; Jessica L Carpenter; Kevin E Chapman; Justice Clark; Raquel Farias-Moeller; William D Gaillard; Marina Gaínza-Lein; Tracy Glauser; Joshua Goldstein; Howard P Goodkin; Réjean M Guerriero; Yi-Chen Lai; Tiffani McDonough; Mohamad A Mikati; Lindsey A Morgan; Edward Novotny; Eric Payne; Katrina Peariso; Juan Piantino; Adam Ostendorf; Tristan T Sands; Kumar Sannagowdara; Robert C Tasker; Dimtry Tchapyjnikov; Alexis A Topjian; Alejandra Vasquez; Mark S Wainwright; Angus Wilfong; Kowryn Williams; Tobias Loddenkemper Journal: Neurology Date: 2020-07-01 Impact factor: 9.910
Authors: Abhishek G Sathe; Ellen Underwood; Lisa D Coles; Jordan J Elm; Robert Silbergleit; James M Chamberlain; Jaideep Kapur; Hannah R Cock; Nathan B Fountain; Shlomo Shinnar; Daniel H Lowenstein; Eric S Rosenthal; Robin A Conwit; Thomas P Bleck; James C Cloyd Journal: Epilepsia Date: 2021-02-10 Impact factor: 5.864
Authors: Marios Charalambous; Holger A Volk; Andrea Tipold; Johannes Erath; Enrice Huenerfauth; Antonella Gallucci; Gualtiero Gandini; Daisuke Hasegawa; Theresa Pancotto; John H Rossmeisl; Simon Platt; Luisa De Risio; Joan R Coates; Mihai Musteata; Federica Tirrito; Francesca Cozzi; Laura Porcarelli; Daniele Corlazzoli; Rodolfo Cappello; An Vanhaesebrouck; Bart J G Broeckx; Luc Van Ham; Sofie F M Bhatti Journal: J Vet Intern Med Date: 2019-10-03 Impact factor: 3.333